Literature DB >> 27440787

Redefining the origin and evolution of ovarian cancer: a hormonal connection.

Carlos Cardenas1, Ayesha B Alvero1, Bo Seong Yun2, Gil Mor3.   

Abstract

Ovarian cancer has the highest mortality of all female reproductive cancers. Late diagnosis, tumour heterogeneity and the development of chemoresistance contribute to this statistic and work against patient survival. Current studies have revealed novel concepts that impact our view on how ovarian cancer develops. The greatest impact is on our understanding that, as a disease, ovarian cancer has multiple cellular origins and that these malignant precursors are mostly derived from outside of the ovaries. In this review, we propose a new concept of a step-wise developmental process that may underwrite ovarian tumorigenesis and progression: (1) migration/recruitment to the ovaries; (2) seeding and establishment in the ovaries; (3) induction of a dormant cancer stage; and (4) expansion and tumor progression. We will discuss the relationship of each step with the changing ovarian function and milieu during the reproductive age and the subsequent occurrence of menopause. The realization that ovarian cancer development and progression occurs in distinct steps is critical for the search of adequate markers for early detection that will offer personalized strategies for prevention and therapy.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  gonadotrophin hypothesis; menopause; ovarian cancer; ovulation

Mesh:

Substances:

Year:  2016        PMID: 27440787     DOI: 10.1530/ERC-16-0209

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells.

Authors:  Sarah J Harmych; Jay Kumar; Mesa E Bouni; Deborah N Chadee
Journal:  Exp Cell Res       Date:  2020-07-07       Impact factor: 3.905

Review 2.  Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression.

Authors:  Hussein Chehade; Roslyn Tedja; Harry Ramos; Tejeshwar Singh Bawa; Nicholas Adzibolosu; Radhika Gogoi; Gil Mor; Ayesha B Alvero
Journal:  Cancers (Basel)       Date:  2022-05-01       Impact factor: 6.575

3.  Constructing an ovarian cancer metastasis index by dissecting medical records.

Authors:  Yanjun Qu; Yanan He; Zhangming Li; Xiuwei Chen; Qian Liu; Shuangshuang Zou; Congcong Kong; Yixiu Liu; Ce Gao; Guangmei Zhang; Wenliang Zhu
Journal:  Oncotarget       Date:  2017-11-06

4.  Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.

Authors:  Heng Zheng; Yan Tie; Zhen Fang; Xiaoai Wu; Tao Yi; Shuang Huang; Xiao Liang; Yanping Qian; Xi Wang; Ruyu Pi; Siyuan Chen; Yong Peng; Shengyong Yang; Xia Zhao; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-07-26

5.  CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary.

Authors:  Shoumei Bai; Wanhong Zhu; Lan Coffman; Anda Vlad; Lauren E Schwartz; Esther Elishaev; Ronny Drapkin; Ronald J Buckanovich
Journal:  Cancers (Basel)       Date:  2019-11-02       Impact factor: 6.639

6.  CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.

Authors:  Jun Shi; Rongfen Huo; Ningli Li; Haichuan Li; Tianhang Zhai; Huidan Li; Baihua Shen; Jing Ye; Ruojin Fu; Wen Di
Journal:  BMC Cancer       Date:  2019-11-25       Impact factor: 4.430

Review 7.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.